TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

OnePath® PRODUCT SUPPORT FOR YOUR PATIENTS

Through OnePath, patients are connected with a dedicated Patient Support Manager who can assist them with:

Silhouette with a heart
  • Facilitating insurance benefits investigation to verify coverage
Specialty pharmacy truck
  • Working with specialty pharmacies to facilitate treatment access
A trained nurse logo
  • Getting patients and/or caregivers started successfully with in-home self-administration training, led by a specially trained nurse
Financial information logo
  • Providing information about financial assistance options       
Educational resources logo
  • Informing patients and caregivers about educational resources available to them

Patients enrolled in OnePath may use the OnePath Mobile App to connect with OnePath and track their health in a personal eDiary.

To enroll in OnePath, complete this start form with your patient and fax it to 1-855–ONEPATH (1-855-663-7284).

OnePath Co-pay Assistance Program

Patients 12 years of age and older with commercial insurance may be eligible for the OnePath Co-pay Assistance Program.

This program will help cover the cost of insurance co-pays for TAKHZYRO at 100% for eligible patients, up to the program maximum.

There are no financial requirements or waiting periods to participate in this program.

IMPORTANT NOTICE: The OnePath Co-pay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Co-payment assistance under the Program is not transferable. The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes you must notify the Program immediately at 1-866-888-0660. Coverage of certain administration charges does not apply for patients residing in Massachusetts, Michigan, Minnesota, Rhode
Island, and Vermont. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.

To enroll in OnePath, complete this start form with your patient and fax it to 1-855–ONEPATH (1-855-663-7284).

Please see complete Important Safety Information below and full Prescribing Information.

Marie quote image

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions... consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-828-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1–800–828–2088, or FDA at 1–800–FDA–1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.